Compare AGEN & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AGEN | HELP |
|---|---|---|
| Founded | 1994 | N/A |
| Country | United States | Canada |
| Employees | 81 | 50 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 208.2M | 233.0M |
| IPO Year | 1999 | N/A |
| Metric | AGEN | HELP |
|---|---|---|
| Price | $5.00 | $7.27 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $14.50 | ★ $51.50 |
| AVG Volume (30 Days) | ★ 8.0M | 1.5M |
| Earning Date | 05-12-2026 | 07-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 100.00 | N/A |
| EPS | ★ 1.02 | N/A |
| Revenue | ★ $42,877,086.00 | N/A |
| Revenue This Year | $107.63 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $4.95 | ★ N/A |
| Revenue Growth | ★ 89.95 | N/A |
| 52 Week Low | $2.71 | $3.76 |
| 52 Week High | $8.70 | $8.55 |
| Indicator | AGEN | HELP |
|---|---|---|
| Relative Strength Index (RSI) | 65.37 | 71.00 |
| Support Level | $3.16 | $5.77 |
| Resistance Level | N/A | $8.55 |
| Average True Range (ATR) | 0.63 | 0.47 |
| MACD | 0.21 | 0.07 |
| Stochastic Oscillator | 35.63 | 91.81 |
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.